An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Sponsor
Hoffmann-La Roche
Study ID
NCT01782690
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • erlotinib — DRUG
    Study participants will receive erlotinib according to Summary of Product Characteristics (SmPC)
  • gemcitabine — DRUG
    Study participants will receive gemcitabine according to Summary of Product Characteristics (SmPC)

Study Details

This observational study will evaluate the impact of rash on survival of patients with metastatic pancreatic cancer treated with erlotinib plus gemcitabine. Further, clinical effectiveness, efficacy and safety will be assessed. Data will be collected for 12 months.

Key Dates

First listed
Feb 4, 2013
Start date
Mar 31, 2012
Status verified
Oct 2017
Primary completion
Feb 28, 2015
Completion
Feb 28, 2015

Study Design

Enrollment
338 participants (actual)

Arms

  • Arm: Erlotinib plus Gemcitabine
    Patients with metastatic pancreatic cancer, who were planned to receive combination therapy of erlotinib and gemcitabine based on the investigator's assessment.

Primary Outcome Measure

Overall Survival Stratified by Rash [ Time Frame: Up to 12 months ]

Related Studies